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asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study
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Background/aim: Oral corticosteroid (OCS)-dependent severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps (SEACRSwNP) would be a suitable phenotype for mepolizumab treatment. This study evaluated the short-term efficacy of mepolizumab
treatment in OCS-dependent SEA-CRSwNP.
Materials and methods: Baseline and 24th week results [daily OCS doses, asthma exacerbation frequency, asthma control test (ACT)
scores, blood eosinophil levels, FEV1 values, and numerical analog scale (NAS) of CRSwNP symptoms] of patients who were treated for
at least 24 weeks with mepolizumab were retrospectively evaluated and compared.
Results: A total of 16 patients were enrolled in the study. Mepolizumab was discontinued in one patient due to side effects. The daily
OCS dosage was reduced from baseline in all patients, and at week 24 OCS was discontinued in 40% of the patients (baseline mean
steroid dose: 9.2 ± 5.2 mg, 24th week: 1.3 ± 1.4 mg; P < 0.001). The number of asthma exacerbations within 24 weeks significantly
decreased after beginning mepolizumab treatment (2.1 ± 2.7 vs. 0.07 ± 0.26; P = 0.012), and a significant increase in ACT scores
(baseline mean ACT: 18 ± 5.7; 24th week mean ACT: 23.3 ± 3; P = 0.006) was observed despite the decrease in daily OCS dosages. There
was no significant difference in FEV1 values between baseline and week 24. Evaluation of the general symptoms of CRSwNP, as per NAS,
revealed that the baseline mean NAS was 5.6 ± 4.4, and the 24th week mean NAS was 3.2 ± 3.2 (P = 0.021).
Conclusion: This is the first real-life study evaluating the short-term efficacy of mepolizumab treatment on OCS-dependent SEACRSwNP. This study demonstrates that mepolizumab is an effective and safe biologic for the treatment of this severe asthma subphenotype.
Key words: Severe asthma, eosinophilic asthma, chronic rhinosinusitis, nasal polyps, mepolizumab, anti-IL5

1. Introduction
The anti-IL5 antibody mepolizumab was approved in
2015 and since then has become an established therapy for
patients with severe uncontrolled eosinophilic asthma1.
In the earliest studies, mepolizumab was administered
to a nonspecific population of patients with moderate,
persistent asthma and variable levels of eosinophilia.
Although no significant clinical results have been reported
for asthma control from the earliest studies, its effectiveness
in eosinophilic asthma is now well documented [1,2].
Clinical trials have shown that mepolizumab displays high
clinical efficacy by reducing exacerbation rates and daily
oral corticosteroid (OCS) intake and enhancing quality
of life. It is apparent that careful selection of patients is
required in order to achieve the best results [3–5].

Among the several different asthma phenotypes,
eosinophilic inflammation occurs in more than 50%
of patients with either atopic or nonatopic asthma.
High eosinophil counts, in both peripheral blood
and the airways, are associated with recurrent disease
exacerbations and severe airflow limitation [6]. Adultonset eosinophilic asthma is increasingly recognized
as one of the most severe asthma phenotypes [7–10].
Another characteristic feature of adult-onset eosinophilic
asthma is comorbid chronic rhinosinusitis with nasal
polyps (CRSwNP), a feature known for many years and,
in some cases, linked with aspirin and other nonsteroidal
antiinflammatory drug hypersensitivities [11–13].
Concern regarding nonallergic, severe eosinophilic
asthma and its associated comorbidities has increased
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with the awareness that this subtype is characterized by
high levels of the proeosinophilic cytokine IL-5, which is
mainly produced by a unique population of type 2 innate
lymphoid cells [14]. We endorse an in-house classification
of asthma phenotypes and a decision-making protocol
which involves the first choice monoclonal antibodies
(mAbs) and potential alternative mAbs in severe asthma
phenotypes [11]. We prefer anti-IL5 treatment, especially
in the OCS-dependent severe eosinophilic asthma with
CRSwNP (SEA-CRSwNP) phenotype.
To the best of our knowledge, no study evaluating the
real-life efficacy of mepolizumab treatment in patients
with OCS-dependent SEA-CRSwNP phenotype has
been carried out to date. According to the literature, data
regarding postmarketing studies that have evaluated the
effects of mepolizumab in real-world settings are scarce
[15,16]. Thus, this short-term single-center study was
carried out in a more specific group of asthmatic patients
treated with add-on biologic therapy with mepolizumab.
2. Methods
Adult patients (>18 years) with OCS-dependent SEACRSwNP phenotype who were treated with mepolizumab
between 2018 and 2019 were retrospectively evaluated.
All patients were treated with high-dose, extrafine
inhaled glucocorticoids (ICS) and a long-acting β2agonist, along with a second controller montelukast
in addition to regular OCS therapy at least 6 months
before mepolizumab treatment. Indications for treatment
with mepolizumab were approved on the basis of the
Turkish Social Security Institution Health Application
Communique, according to which, mepolizumab can be
administered to patients with severe eosinophilic asthma
who have: a) blood eosinophil count ≥300 cells/µL (≥150
cells/µL if the patient is under long-term, regular OCS
therapy) and b) controlled or uncontrolled asthma treated
with regular systemic steroids for at least 6 months and/
or uncontrolled asthma (approximately two attacks per
year requiring systemic corticosteroids for at least 3 days)
despite use of a high combination dosage of ICS (>800 µg/
day budesonide, or equivalent) and long-acting inhaled β2
agonist for at least one year2. However, we have reduced
the criterion, and mepolizumab was employed only in
patients with GINA step 5 OCS-dependent SEA-CRSwNP
(uncontrolled, partially controlled, or, in cases where
OCS side effects developed, even in cases of controlled
asthma). Mepolizumab was administered subcutaneously
at a dose of 100 mg every four weeks for at least 12 weeks.
Mepolizumab was continued if there was a clinical
response at week 12. Those patients who completed at least
24 weeks of treatment were included in the study.

Throughout the study period parameters including
ACT score, blood eosinophil count, and FEV1 were
measured at baseline, week 12, and week 24 after the first
injection of mepolizumab. In addition, the number of
asthma exacerbations (exacerbations occurring within the
previous 24 weeks) and daily intake of OCS (presented
as methyl-prednisone equivalent in milligrams) were
also recorded, respectively, at baseline and at week 24 of
mepolizumab treatment.
The scores for severity of nasal polyposis on the
numerical analog scale (NAS) were assessed by asking
patients to indicate the severity of their CRSwNP using
a 0 to 10 scale (0: no symptoms; 10: worst symptoms
possible) and the irritability of the following symptoms in
general: rhinorrhea, mucus in the throat, nasal blockage,
and loss of smell. The NAS score for the loss of smell was
evaluated separately. Changes in the severity of nasal
polyposis according to NAS score from baseline to the
24th week were also recorded. In addition, the side effects
of mepolizumab were assessed for all patients.
2.1. Differentiation of severe asthma from difficult
asthma
Drug adherence; inhaler technique; and comorbidities
including allergic rhinitis, chronic rhinosinusitis/nasal
polyps, gastroesophageal reflux, obstructive sleep apnea
syndrome; and trigger factors like allergens, smoking,
occupational allergens and/or irritants, ACE inhibitors, and
nonspecific beta-blockers which interfered with disease
control were investigated for all patients. Measures taken
for these comorbidities and triggers, drug compliance, and
techniques were analyzed. All patients under GINA step
5 treatment with controlled or uncontrolled asthma were
considered to be severely asthmatic, and OCS-dependent
SEA-CRSwNP was identified as the appropriate asthma
phenotype for mepolizumab treatment in these patients.
Since this asthma phenotype is associated with high
eosinophilia, other diseases associated with higher
peripheral eosinophilia and accompanied by asthma or
asthma-like symptoms, such as eosinophilic granulomatosis
with polyangiitis, allergic bronchopulmonary aspergillosis,
chronic eosinophilic pneumonia, hypereosinophilic
syndrome, Loffler’s syndrome, and pulmonary involvement
of connective tissue diseases were ruled out.
2.2. Definitions
2.2.1, Asthma exacerbations
An exacerbation was defined as a worsening of asthma
symptoms requiring OCS at least three days a week or an
increase in the OCS dose.
2.2.2. Chronic rhinosinusitis (CRS)
All CRS subjects met the criteria for CRS as defined by the
American Academy of Otolaryngology–Head and Neck

Turkish Social Security Institution Health Application Communique [online]. Website: http://www.mevzuat.gov.tr/Metin.
Aspx?MevzuatKod=9.5.17229&MevzuatIliski=0&sourceXmlSearch= (25 september 2019, date last accessed)
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Surgery Chronic Rhinosinusitis Task Force. The diagnosis
of CRS was based on the presence of clinical symptoms
(i.e. nasal congestion, rhinorrhea, facial pressure, and
hyposmia) for more than 12 weeks in addition to the
objective evidence of chronic inflammatory disease
on sinus CT imaging or nasal endoscopy. Sinonasal
involvement was assessed by paranasal sinus computerized
tomography (PNCT) and nasal endoscopy [17].
2.2.3. CRSwNP
CRSwNP is characterized by the occurrence for more than
12 weeks of symptoms such as nasal discharge, stuffiness,
facial pressure or pain, dysfunction or loss of the sense of
smell, and cough from postnasal drip and by the polypoid
inflammation filling the nasal airway in the PNCT [18].
2.2.4. NAS
In NAS, the response to “How troublesome are your
CRSwNP symptoms?” is rated from 0 to 10 (0 = not
troublesome, 10 = worst symptoms possible).
2.2.5. Treatment response to mepolizumab
Based on placebo-controlled, phase III studies,
recommendations published by the National Institute for
Health and Care Excellence (NICE) define the reduction
of the exacerbation rate by at least 50%, or a clinically
significant reduced dose of continuous OCS, as adequate
response criteria [4,5,]3.
2.3. Laboratory, functional, and imaging tests
The tests included blood eosinophilia (reference range:
<200 cells/mm3), C-reactive protein (CRP; reference range:
0–6 mg/L), erythrocyte sedimentation rate (ESR; reference
range: 3–20 mm/h), total immunoglobulin E (IgE; reference
range: 0–100 IU/mL), Aspergillus specific IgE, antinuclear
antibody, urinalysis, liver and renal function tests, parasite
stool examination, creatine kinase, pulmonary function
tests [including FEV1, forced vital capacity (FVC), and
FEV1/FVC], thorax computed tomography, PNCT, and
electromyography if the patients exhibited symptoms
of peripheral neuropathy. The authors also requested
advanced laboratory tests for eosinophilic granulomatosis
with polyangiitis (EGPA), hypereosinophilic syndrome
(HES), and lymphoreticular malignancy among patients
who had >10% blood eosinophils (such as vitamin B12,
antineutrophil cytoplasmic antibody, troponin, FIP1like-1platelet-derived growth factor receptor alpha, JAK2 mutation, and Philadelphia chromosome; abdominal
ultrasonography was carried out if suggested by
hematologic consultation).
2.4. Glucocorticoid reduction phase scheme
The dose of methylprednisone was reduced every 4 weeks
according to a predefined schedule (Table 1) if the patient

Table 1. Glucocorticoid reduction phase scheme.
Methylprednisolone Dose (mg/day)
20.0

16.0

12.0

10.0

8.0

6.0

4.0

16.0

12.0

10.0

8.0

6.0

4.0

2.0

12.0

10.0

8.0

6.0

4.0

2.0

2.0*

10.0

8.0

6.0

4.0

2.0

2.0*

0.0

8.0

6.0

4.0

2.0

2.0*

0.0

0.0

6.0

4.0

2.0

2.0*

0.0

0.0

0.0

4.0

2.0

2.0*

0.0

0.0

0.0

0.0

2.0

2.0*

0.0

0.0

0.0

0.0

0.0

2.0*

0.0

0.0

0.0

0.0

0.0

0.0

*Taken as 2.0 mg administered every other day.

had not had an exacerbation with a decrease in ACT score.
In patients who were receiving a daily dose of 8 mg or
more of methylprednisone at baseline, the dose of the drug
was not reduced to zero without consulting endocrinology
due to concern regarding withdrawal effects.
All patients under follow-up at our asthma outpatient
clinic provided written informed consent. Ethics approval
was obtained from the Erciyes University ethics committee
(approval date and number: 12 August; 2019-20019/472).
2.5. Statistical analysis
Data were entered into SPSS software version 17.0 (SPSS
Inc., Chicago, IL, USA), and analyses were made using the
same program. All continuous variables were presented as
mean ± standard deviation (SD) due to the small sample
size. For all nonparametric variables between and within
groups, comparisons were made using the Mann–Whitney
U-test and Wilcoxon test, respectively. P values <0.05 were
considered significant in all analyses.
3. Results
Data from 16 patients with OCS-dependent SEA-CRSwNP
who underwent treatment with mepolizumab were
analyzed. All patients were classified as step 5 according
to the Global Initiative for Asthma (GINA)1 and had
uncontrolled asthma despite maximal therapy. The mean
age of the patients was 48.6 ± 11.9 years. The mean duration
of the disease and the duration of regular OCS use prior to
the initiation of mepolizumab treatment were 12.9 ± 6.6
years and 5.1 ± 2.6 years, respectively. Females accounted
for 81% of all the study subjects. Of the 16 patients, 14
(88%) were nonsmokers. Patient characteristics are shown
in Table 2.

Mepolizumab for treating severe refractory eosinophilic asthma. National Institute for Health and Care Excellence (NICE) [online].
Website: https://www.nice.org.uk/guidance/ta431 (19 July 2019, date last accessed)
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Table 2. Characteristics of the patients.
N = 16
Females (%)

13 (81)

Age, years, mean ± SD

48.6 ± 11.9

Smoking story (%)
Never smoked
Ex-smoker
Active smoker

14 (88)
1 (6)
1 (6)

Asthma duration, years, mean ± SD

12.9 ± 6.6

Mean clinical follow-up duration, years ± SD

5.1 ± 2.6

NERD (%)

10 (63)

Atopy (%)

3 (19)

Baseline total IgE levels, IU/mL, mean ± SD

545 ± 977

NERD: NSAID-exacerbated respiratory disease.

Disease control was evaluated using ACT at baseline
with a mean value of 18.2 ± 5.5. In addition, a lung
function test prior to mepolizumab treatment evidenced a
mean FEV1 of 81% ± 30. All patients were receiving daily
OCS therapy before mepolizumab treatment (a mean
dose of 8.9 ± 5.2 mg of methyl-prednisolone). The mean
eosinophil count at baseline was 561 ± 591 cells/µL. The
mean eosinophil percentage was 5.3 ± 5.7%.
The number of asthma exacerbations as well as the
mean eosinophil counts decreased, and ACT results
improved under daily OCS treatment before initiation of
mepolizumab, in comparison to the time before regular
OCS intake. There was also a nonsignificant increase in
FEV1 values after starting regular daily OCS (Table 3).
Mepolizumab treatment was found to be very effective
in all study subjects. With regard to adverse events, only

one patient showed side effects including arthralgia, and
malaise occurred on the day after administration of the first
two doses. The patient also had a third reaction on the day
following administration, and fever, nausea, and vomiting were
reported. Mepolizumab was discontinued, and this patient
was excluded from the study. The patient was symptom-free
during the follow-up period. Further comparisons between
study subjects included only the remaining 15 patients.
When comparing the change in blood eosinophil counts,
daily OCS doses, and ACT scores at baseline and week 12 of
mepolizumab treatment, a marked decrease in peripheral
eosinophil counts (5.5% ± 5.8 vs. 1.3% ± 0.7; P = 0.013) and
an increase in ACT scores (18 ± 5.7 vs. 22.5 ± 3.6; P = 0.011)
were observed. The OCS dose was decreased in all of the
patients; the daily OCS dosage was completely withdrawn
in 3 (20%) patients, and 15 out of 15 patients (100%) were
classified as treatment responders at week 12. No marked
changes in FEV1 values were observed at this time point (80 ±
30.7% vs. 84 ± 26%) (Table 4).
After 24 weeks of mepolizumab treatment, the decrease
in blood eosinophil counts (baseline eosinophil count: 5.5 ±
5.8%, 24th week eosinophil count: 1.9 ± 1.4%; P = 0.029) and
improvement in ACT scores (baseline ACT: 18 ± 5.7, 24th
week ACT: 23.3 ± 3; P = 0.006) continued. The OCS dose was
additionally reduced in 9 (60%) patients when compared to
12th week results, and OCS was completely withdrawn in 6
of 15 (40%) patients at week 24. A significant decrease in the
24-week exacerbation rates of pre- and postmepolizumab
treatment was observed (2.1 ± 2.7 vs. 0.07 ± 0.26; P =
0.012) (Table 4). Despite the decrease in daily OCS dosages,
improvement in all parameters was seen at week 24 under
mepolizumab treatment.
Comparison of OCS dosage, number of asthma
exacerbations, ACT, FEV1, and blood eosinophils at the
beginning of mepolizumab treatment and at the 12th and
24th weeks is shown in Figure.

Table 3. Comparison of the clinical, laboratory, and functional parameters prior to and after OCS.
N=16

Prior to OCS

Under OCS prior to
Mepolizumab

P

Number of asthma exacerbations
in the last 24 weeks, mean ± SD

9.6 ± 8.7

2 ± 2.6

0.001

ACT, mean ± SD

11.9 ± 3.7

18.2 ± 5.5

<0.001

Blood eos %, mean ± SD

13.3 ± 8.9

5.3 ± 5.7

<0.001

Blood eos count mean ± SD

1371 ± 1182

561 ± 591

0.002

FEV1 %, mean ± SD

71.4 ± 19

81 ± 30

0.241

FEV1 L/s, mean ± SD

1920 ± 805

2091 ± 962

0.425

ACT: Asthma control test, eos: eosinophil, OCS: oral corticosteroid
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Table 4. Comparison of the clinical, laboratory, and functional parameters at the baseline and 12th and 24th weeks.
N=15

Premepolizumab

Mepolizumab
12th Week

P*

Mepolizumab
24th Week

P**

Methylprednisolone equivalent
systemic steroid dose, mg, mean ± SD

9.2±5.2

2.8±2.2

<0.001

1.3±1.4

<0.001

Number of asthma exacerbations
in the last 24 weeks, mean ± SD

2.1 ± 2.7

0.07 ± 0.26

-

0.07 ± 0.26

0.012

ACT mean ± SD

18 ± 5.7

22.5 ± 3.6

0.011

23.3 ± 3

0.006

Eos %, mean ± SD

5.5 ± 5.8

1.3 ± 0.7

0.013

1.9 ± 1.4

0.029

Eos count mean ± SD

580 ± 607

106 ± 73

0.01

177 ± 137

0.019

FEV1 %, mean ± SD

80 ± 30.7

84 ± 26

0.342

84.6 ± 26

0.392

FEV1 L/s, mean ± SD

2092 ± 995

2156 ± 922

0.434

2232 ± 875

0.533

ACT: Asthma control test, eos: eosinophil.
*Comparison of premepolizumab and mepolizumab, 12th week.
**Comparison of premepolizumab and mepolizumab, 24th week.

During the 6-month mepolizumab treatment,
demographics, baseline blood eosinophil counts,
exacerbation rates, FEV1 values, and ACT scores were
found to be similar regardless of whether OCS was
completely withdrawn in the patients.
On a 10 point NAS, the severity of CRSwNP symptoms
decreased from 5.6 ± 4.4 points to 3.2 ± 3.2 points (P =
0.021), and the severity of loss of smell decreased from 4
± 5.1 points to 2.4 ± 4.2 points (P > 0.05) after 24 weeks of
mepolizumab treatment.
4. Discussion
This is the first real-life study evaluating the short-term
(24 weeks) efficacy of mepolizumab treatment in a specific
subphenotype of asthma. Our study showed that in patients
with OCS-dependent SEA-CRSwNP phenotype, the OCS
dose was decreased in all patients, and 40% of them no
longer required OCS after 24 weeks of mepolizumab
treatment. In addition to the decrease in daily OCS doses, a
decrease in the frequency of exacerbations and an increase
in ACT scores were observed. However, there were no
significant differences in FEV1 values between week 24 and
baseline.
Both severe eosinophilic asthma and nasal polyposis are
characterized by marked local eosinophilic inflammation
[19]. IL-5 appears to play a key role in the pathogenesis
of CRSwNP and eosinophilic asthma [19–23]. In addition,
suggestions were made in the severe asthma guidelines
of GINA regarding preferred biologics for the type2 high asthma phenotype, and it was emphasized that
factors determining the response to treatment should be
taken into consideration .1 Therapy should be initiated
with anti-IL5/anti-IL5R mAbs in patients with severe

uncontrolled asthma who have a blood eosinophil count
of ≥300/µL. Factors that may predict a good response to
anti-IL5/IL5R biologics are defined as follows: (a) higher
blood eosinophil count (strongly predictive), (b) more
frequent severe exacerbations during the previous year
(strongly predictive), (c) adult-onset asthma, (d) nasal
polyposis, and e) maintenance with OCS at baseline. The
efficacy of mepolizumab has been reported, separately, in
OCS-dependent asthma, severe eosinophilic asthma, and
CRSwNP [3–5,24–26]. Therefore, the OCS-dependent
SEA-CRSwNP phenotype appears to be the most
appropriate phenotype for mepolizumab. In our study,
all study subjects presented with a history of frequent
exacerbations, higher eosinophil levels, OCS-dependency,
and CRSwNP. For all of these reasons, we decided to
initiate mepolizumab therapy for this subphenotype of
asthma.
One of the main endpoints of all biologics is the
withdrawal of the use of OCS in severe asthma [27]. In
this real-life study, all patients were prescribed with daily
OCS (9.2 ± 5.2 mg of methyl-prednisone, or equivalent).
The OCS dose was successfully reduced in all patients, and
40% patients completely discontinued OCS after 24 weeks
of mepolizumab therapy. Compared to baseline, at week
24 a significant decrease in the frequency of exacerbations
and an increase in ACT scores were observed, in addition
to the decrease in daily OCS doses. In the large, placebocontrolled trials, treatment with mepolizumab significantly
reduced exacerbation rates and daily OCS doses [3–5].
The Steroid Reduction with Mepolizumab Study (SIRIUS)
demonstrated that mepolizumab, in addition to decreasing
asthma exacerbations and improving the quality of life,
was also capable of significantly diminishing daily OCS
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Figure. Comparison of OCS dosage (A), number of asthma exacerbations (B), ACT (C), FEV1 (D), and blood eosinophils (E) at the
beginning of mepolizumab and at the 12th and 24th weeks after beginning treatment.
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intake (reduction: 50%, complete discontinuation: 14%)
[3]. However, the OCS reduction (100%) and complete
discontinuation (40%) rates in our study were much higher
at week 24. This positive outcome could be due to the fact
that the add-on therapy with mepolizumab was initiated
in a specific eosinophilic asthma subphenotype that may
derive a higher potential benefit from mepolizumab
therapy. In another real-life study supporting the results of
the present study, Pelaia et al. established that OCS could
be reduced in all patients with significant reduction in
exacerbations after 24 weeks of initiation of mepolizumab
therapy in patients with OCS-dependent severe
eosinophilic asthma [28]. The common feature of these
studies is that all of the patients in both studies were OCSdependent, and the initial eosinophil counts during OCS
therapy were higher (580 ± 607 cells/μL, 647.1 ± 274.7
cells/μL, respectively). However, nasal polyp ratios were
not reported in this study. These two real-life studies have
shown that the early results from mepolizumab are quite
good, especially in patients with high blood eosinophilia
and OCS dependency. Prioritizing these patients will be
more meaningful in terms of treatment success among
patients indicated for mepolizumab therapy.
In the present study, the clinically relevant improvement
in asthma control elicited by mepolizumab was paralleled
by a prominent and sustained decrease in blood eosinophil
counts. This finding confirms the results of several largecohort and real-life studies [4,28]. Undeniably, blood
eosinophils are now considered a reliable biomarker
for predicting and assessing the therapeutic efficacy of
mepolizumab in severe eosinophilic asthma [29,30]. The
initial high eosinophil levels in patients in the present study
were associated with a good response to mepolizumab.
An increased blood eosinophil count (300 or 400 cells/
μL) in asthmatic patients is associated with an increased
risk of exacerbations [31,32]. Therefore, one of the goals
of mepolizumab treatment that should be emphasized is
keeping blood eosinophils below these cut-off values in
severe eosinophilic asthma [33]. In the present study, the
remarkable decrease in blood eosinophil levels evoked by
mepolizumab was paralleled by a reduction in the rate
of asthma exacerbation and an improvement in asthma
control.
Contradictory reports on the effects of mepolizumab
on FEV1 have been published. Some studies have indicated
a modest increase in FEV1 with mepolizumab therapy
[5,16,24], while others claim that FEV1 did not improve
with the administration of mepolizumab [1,2,4,34]. In the
present study, no significant change in FEV1 values was
noted after 12 or 24 weeks of mepolizumab treatment,
compared to baseline. Yet, the important point here is that
there was no deterioration in pretreatment FEV1 values,
despite dosage reduction or discontinuation of OCS.

The SIRIUS study, which included OCS-dependent
eosinophilic asthma patients, reported the rate of nasal
polyps to be 23%. In another study which included
OCS-dependent eosinophilic asthma patients, this rate
was 30% [3,24]. However, the effect of mepolizumab
on nasal polyps was not evaluated in these studies. In a
randomized, double-blind, placebo-controlled study
recruiting adult patients with recurrent nasal polyposis
requiring surgery, patients received 750 mg intravenous
mepolizumab. A significant improvement in all individual
VAS symptom scores was observed in the mepolizumab
group, in comparison to placebo [25]. In the present study,
a significant improvement in NAS scores that assessed
general CRSwNP symptoms at 24 weeks (rhinorrhea, nasal
blockage, postnasal drip, and loss of smell) was observed.
However, there was no significant improvement when NAS
was evaluated only for smell loss. We speculate that other
pathways may be more dominant in the development of
eosinophilic inflammation in the nasal polyposis in these
subgroups (IL4/IL13 dominant type-2 inflammation)
or that the dose of mepolizumab may be insufficient to
reduce eosinophilic inflammation at the tissue level (the
mepolizumab dose used in the two, abovementioned
studies on CRSwNP was 750 mg; the dose used in the
present study was 100 mg).
The major limitations of the present study were
the inclusion of a small number of patients and its
retrospective design. We could not recruit a high number
of patients as the study was conducted in a very specific
patient cohort. Although we obtained good clinical
results from mepolizumab therapy for a specific asthma
subphenotype, a large-scale series is still necessary for
robust results. Another limitation was that we only
compared asthma exacerbation rates before and after
6 months of mepolizumab initiation. As exacerbations
mainly occur during winter, assessment for at least 12
months is necessary to properly reflect the exacerbation
rates [35]. However, patients who received mepolizumab
for at least 6 months passed through the autumn of 2018
and winter and spring of 2019. In other words, the patients
were treated with mepolizumab during the period in which
the risk of asthma exacerbation is high, and the results
were compared 6 months before mepolizumab initiation.
The authors speculate that decreases in exacerbations
during a 12-month period may be even greater.
In conclusion, the authors found that subcutaneous
mepolizumab administration significantly decreased
blood eosinophil levels, asthma exacerbations, and daily
OCS doses. These excellent therapeutic effects were
associated with a marked improvement in symptoms as
well as a very good short-term safety profile for the drug
and its tolerability in this single-center study. Therefore,
the availability of mepolizumab in daily medical practice
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undoubtedly represents a valuable advancement in the
management of patients with OCS-dependent SEACRSwNP. The ideal scenario for therapeutic intervention
would be specific selection criteria with a clear prediction
of clinical benefits. This small study was clinically directed
and highlighted the importance of patient selection for
investigating the use of mepolizumab in severe asthma.

Nevertheless, further extended real-life investigations are
required to confirm the results obtained in our study.
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